Cargando…
Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B
Triazole resistant A. fumigatus has been documented in many parts of the world. In the Netherlands, incidence is now above 10% and results in the need for long-term parenteral therapy with liposomal amphotericin B (LAmB). The long terminal half-life of LAmB suggests that intermittent dosing could be...
Autores principales: | van de Peppel, Robert J, Schauwvlieghe, Alexander, Van Daele, Ruth, Spriet, Isabel, van't Wout, Jan W, Brüggemann, Roger J, Rijnders, Bart J A, Hendriks, Bart J C, de Boer, Mark G J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527269/ https://www.ncbi.nlm.nih.gov/pubmed/31965178 http://dx.doi.org/10.1093/mmy/myz134 |
Ejemplares similares
-
Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
por: Adler-Moore, Jill, et al.
Publicado: (2019) -
777. Experience with Liposomal Amphotericin B in Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Burnett, Yvonne, et al.
Publicado: (2019) -
Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
por: Groll, Andreas H, et al.
Publicado: (2019) -
Liposomal amphotericin B—the past
por: Brüggemann, R J, et al.
Publicado: (2022) -
OPAT: outpatient parenteral antimicrobial therapy
Publicado: (2020)